ATE536553T1 - Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse - Google Patents

Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse

Info

Publication number
ATE536553T1
ATE536553T1 AT08837800T AT08837800T ATE536553T1 AT E536553 T1 ATE536553 T1 AT E536553T1 AT 08837800 T AT08837800 T AT 08837800T AT 08837800 T AT08837800 T AT 08837800T AT E536553 T1 ATE536553 T1 AT E536553T1
Authority
AT
Austria
Prior art keywords
adverse cardiovascular
major adverse
human
cerebrovascular events
cerebrovascular event
Prior art date
Application number
AT08837800T
Other languages
German (de)
English (en)
Inventor
Pieter Muntendam
Rajalakshmi Balasubramanian
Rene Myers
Original Assignee
Bg Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bg Medicine Inc filed Critical Bg Medicine Inc
Application granted granted Critical
Publication of ATE536553T1 publication Critical patent/ATE536553T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01JELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00Particle spectrometers or separator tubes
    • H01J49/0009Calibration of the apparatus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/7454Tissue factor (tissue thromboplastin, Factor III)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2871Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/325Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Electrotherapy Devices (AREA)
AT08837800T 2007-10-10 2008-10-10 Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse ATE536553T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99856307P 2007-10-10 2007-10-10
US99875607P 2007-10-11 2007-10-11
PCT/US2008/079553 WO2009049189A2 (en) 2007-10-10 2008-10-10 Methods for detecting major adverse cardiovascular and cerebrovascular events

Publications (1)

Publication Number Publication Date
ATE536553T1 true ATE536553T1 (de) 2011-12-15

Family

ID=40289424

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08837800T ATE536553T1 (de) 2007-10-10 2008-10-10 Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse

Country Status (10)

Country Link
US (1) US20110045514A1 (enExample)
EP (1) EP2210108B1 (enExample)
JP (1) JP2011501133A (enExample)
CN (1) CN101939651A (enExample)
AT (1) ATE536553T1 (enExample)
AU (1) AU2008310669A1 (enExample)
CA (1) CA2702268A1 (enExample)
ES (1) ES2374762T3 (enExample)
IL (1) IL204922A0 (enExample)
WO (1) WO2009049189A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8620738B2 (en) * 2006-08-31 2013-12-31 Visa U.S.A. Inc Loyalty program incentive determination
GB0717637D0 (en) 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
EP2199956A1 (en) * 2008-12-18 2010-06-23 Siemens Aktiengesellschaft Method and system for managing results of an analysis process on objects handled along a technical process line
JP5728488B2 (ja) 2009-11-13 2015-06-03 ビージー メディシン, インコーポレイテッド 心筋梗塞のリスクファクターおよび予測
ES2728120T3 (es) * 2010-01-29 2019-10-22 Metanomics Gmbh Medios y procedimientos para diagnosticar insuficiencia cardíaca en un sujeto
BR112012018771A2 (pt) * 2010-01-29 2017-06-20 Metanomics Gmbh ''método para dianosticar insuficência cardíaca em um sujeito''
CN106055895B (zh) * 2010-09-15 2021-02-19 Dh科技发展私人贸易有限公司 产物离子谱的数据独立获取及参考谱库匹配
EP2592422A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP3968026A1 (en) 2012-03-26 2022-03-16 XCellCure, LLC Device and method for detection of analytes
AU2014227891A1 (en) * 2013-03-15 2015-10-08 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
KR101660328B1 (ko) 2014-01-14 2016-09-27 한국과학기술연구원 심혈관 질환 진단용 바이오 마커
US9933425B2 (en) 2014-04-10 2018-04-03 MEP Equine Solutions LLC Method for the quantification of parasite eggs in feces
EP3172564A4 (en) * 2014-07-18 2018-06-27 Genova Diagnostics, Inc. Use of an evidence-based, translational algorithm to, inter alia, assess biomarkers
US20180238914A1 (en) * 2015-08-19 2018-08-23 Metanomics Gmbh Means and methods for diagnosing cardiac disease in a subject
WO2017028308A1 (en) * 2015-08-20 2017-02-23 Bgi Shenzhen Biomarkers for coronary heart disease
CN105223264B (zh) * 2015-09-21 2017-12-29 广东联捷生物科技有限公司 一种质谱定量分析的模拟内标方法、装置及应用
CN105486778B (zh) * 2016-01-25 2017-11-03 齐炼文 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物
CN105445408B (zh) * 2016-01-25 2018-06-12 齐炼文 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物
CN105866261A (zh) * 2016-03-24 2016-08-17 中国药科大学 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物群
WO2017178453A1 (en) * 2016-04-14 2017-10-19 Roche Diagnostics Gmbh Method for determining a concentration of a target analyte in a sample of bodily fluid
CA3087305A1 (en) * 2017-12-13 2019-06-20 Glx Analytix Aps Biomarkers for multiple sclerosis
JP7280582B2 (ja) * 2018-09-12 2023-05-24 株式会社島津製作所 心房細動指標値の測定方法
CN109799296A (zh) * 2019-01-28 2019-05-24 江南大学 一种用于细胞非靶向代谢组学分析的样品前处理方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP1904846A4 (en) 2005-06-29 2009-03-18 Rules Based Medicine Inc METHOD AND KITS FOR THE DIAGNOSIS OF ACUTE CORONARY SYNDROME
WO2007124439A2 (en) * 2006-04-21 2007-11-01 Rules-Based Medicine, Inc. Diagnosis of stroke using metalloproteinase or transaminase

Also Published As

Publication number Publication date
US20110045514A1 (en) 2011-02-24
WO2009049189A3 (en) 2009-06-18
JP2011501133A (ja) 2011-01-06
EP2210108A2 (en) 2010-07-28
AU2008310669A1 (en) 2009-04-16
IL204922A0 (en) 2010-11-30
EP2210108B1 (en) 2011-12-07
CN101939651A (zh) 2011-01-05
WO2009049189A2 (en) 2009-04-16
ES2374762T3 (es) 2012-02-21
CA2702268A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
ATE536553T1 (de) Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse
Dvorak et al. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice-an exploratory case-control study
ATE548656T1 (de) Verfahren zur identifizierung von patienten mit erhöhter wahrscheinlichkeit des auftretens eines ovarialkarzinoms und zusammensetzungen dafür
BR112014016158A2 (pt) medições exatas de analito para tira de teste eletroquímica com base na(s) característica(s) física(s) detectada(s) da amostra contendo o analito
TW200617380A (en) Concentration determination in a diffusion barrier layer
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
MX2007014815A (es) Metodos de inmunoanalisis mejorados.
MX357119B (es) Microarn plasmáticos para la detección de cáncer colorrectal temprano.
AR103935A1 (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
RU2008136193A (ru) Детектирование рака по повышенным уровням bcl-2
WO2009137015A3 (en) Biomarkers of ionizing radiation
BR112013003391B8 (pt) Método para diagnosticar câncer pancreático em um indivíduo
JPWO2016163539A1 (ja) 肝疾患の病態を判別する方法
EP2569635A4 (en) METHOD FOR DIAGNOSIS AND / OR TREATMENT OF ENZEPHALITIS OR EPILEPSY
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
ATE492815T1 (de) Diagnostik-biomolekül(e)
RU2019104870A (ru) Комбинированный тест на наличие колоректального рака
MX2012007009A (es) Método para diagnosticar un tumor maligno.
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
ATE526584T1 (de) Nachweisverfahren und nachweisreagens für autoimmune pankreatitis oder fulminanten typ-1- diabetes
ATE420364T1 (de) Verfahren zur magenkrebsvorhersage
ATE475098T1 (de) Verfahren zur messung von plasmaspiegeln von pentraxin ptx3